Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) made a significant announcement regarding its entry into an Agreement and Plan ...

RVU-120 is under clinical development by Ryvu Therapeutics and currently in Phase II for Anemia. According to GlobalData, Phase II drugs for Anemia have a 53% phase transition success rate (PTSR) ...

RVU-120 is under clinical development by Ryvu Therapeutics and currently in Phase II for Secondary Myelofibrosis.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

The six subunit ORC is essential for initiation of DNA replication in eukaryotes. Cancer cell-lines in culture can survive and replicate DNA replication after genetic inactivation of individual ORC ...

The Swedish rare disease company, which opened North American headquarters in Chicago earlier this year, will pick up an ...

Vincerx Pharma, Inc. filed an 8-K form with the Securities and Exchange Commission on December 20, 2024, announcing the entry into a binding term sheet with Oqory, Inc., a Delaware corporation, and ...

肝脏作为人体的重要器官在代谢、解毒、合成蛋白质等方面发挥着不可或缺的作用。然而，急性肝衰竭（ALF）却如同一头凶猛的“病魔”，来势汹汹，严重威胁着患者的生命健康。ALF的病情进展极为迅速，肝细胞大量 坏死 ...